Risk Prediction Model of Cardiovascular Events in Patients With Schizophrenia

Sponsor
Shanghai Mental Health Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05498571
Collaborator
(none)
1,500
1
13
115.6

Study Details

Study Description

Brief Summary

Schizophrenia is a serious mental illness that has a great impact on social function. Studies have evidenced that schizophrenia patients live 10-20 years less than general population.It mainly dues to high cardiovascular risk. How to improve patients' survival rates? At present, there is an objective model to assess cardiovascular risk among schizoprenia patients in England - PRIMROSE.But there is a lack of model for schizophrenia patients in china. In order to better guide clinical practice, we are now exploring a domestic cardiovascular risk prediction model to raise people's awareness.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Schizophrenia is a common severe mental disorder with high rate of disability, which seriously affects patients' life.It is necessary to take long-term therapy to control symptoms or prevent recurrence. Studies have found that schizophrenia patients live on average ten to twenty-five years less than others. The main reason for high rates of mortality and disability is the high risk of cardiovascular events.There are few domestic large-scale studys on the risk of cardiovascular events in schizophrenia, thus they have not formed objective tools to assess cardiovascular risk. If this risk can be objectively assessed and predicted at an early stage, it is expected to reduce the risk of cardiovascular events and thus reduce mortality.At present, there are mature tools for assessing the risk of cardiovascular events in patients, such as Framingham, PRIMROSE, etc.The latter is the new tool for assessing cardiovascular events in patients with severe mental disorders. This study used a retrospective cohort design to collect the history of hospitalized schizophrenia patients within 2 years, collect relevant informations about cardiovascular events. The investigators validate the PRIMROSE model in China and explore the risk prediction model of cardiovascular events in schizophrenia patients.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    1500 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Risk Prediction Model of Cardiovascular Events in Patients With Schizophrenia
    Actual Study Start Date :
    Dec 1, 2021
    Anticipated Primary Completion Date :
    Dec 31, 2022
    Anticipated Study Completion Date :
    Dec 31, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Schizophrenia Patients

    We collect relevant information, review cardiovascular events in schizophrenia patients.

    Outcome Measures

    Primary Outcome Measures

    1. cardiovascular events [2-10 years]

      Cardiovascular events end points were defined as the first occurrence of fatal or non-fatal cardiovascular events.They were collected and individually validated using data from the clinical diagnosis items, including data from emergency room visits, cardiology consultations, and tests (MRI,CT,ECG,Troponin I,Troponin T,coronary angiography etc). Fatal and non-fatal cardiovascular events are defined as myocardial infarction, Angina, coronary heart disease, coronary artery surgery, cerebrovascular accident and transient ischemic attack, peripheral artery disease or revascularization;cardiovascular and all-cause mortality.We need to record the time of the first cardiovascular events and diagnosis items.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients hospitalized before July 1, 2020;and hospitalized between July 1 2020-June 30, 2022;

    • Meeting the ICD-10 diagnostic criteria for "Schizophrenia, Schizotypy, delusional disorder"or ICD-11 diagnostic criteria for "Schizophrenia and other Primary Mental Disorders";

    • At least 2 doctors in charge of ward make definitive diagnoses;

    • Age ≥18 years old, male and female are not limited.

    Exclusion Criteria:
    • Researchers consider patients unsuitable for the study;

    • past history of cardiovascular disease (fatal and nonfatal cardiovascular events defined as myocardial infarction, Angina, coronary heart disease, coronary artery surgery, cerebrovascular accident and transient ischemic attack, peripheral arterial disease or revascularization) prior to antipsychotic therapy ;

    • use of lipid lowering drugs or antiplatelet drugs, such as aspirin、statins ,prior to antipsychotic therapy.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Shanghai Mental Health Center Shanghai Shanghai China 200030

    Sponsors and Collaborators

    • Shanghai Mental Health Center

    Investigators

    • Study Director: Shengke Pan, Master, Shanghai Mental Health Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Shanghai Mental Health Center
    ClinicalTrials.gov Identifier:
    NCT05498571
    Other Study ID Numbers:
    • 2020-YJ13
    First Posted:
    Aug 12, 2022
    Last Update Posted:
    Aug 12, 2022
    Last Verified:
    Apr 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 12, 2022